AdAlta, GPCR Therapeutics partner on new cancer treatment approach

The companies will evaluate AdAlta’s CXCR4 inhibiting i-bodies as cancer therapeutics, using GPCR’s combination inhibition technique. Credit: Lucas Vasques on Unsplash.